Behnam Bozorgnia, MD
Advanced Heart Failure and Transplant Cardiology · Philadelphia, PANPI 1629244090
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,375 of the $106,993 with a category attached, or 84.5%. 20 manufacturers reported payments, led by Boehringer Ingelheim at 46.9% of the total. Reporting peaked in 2022 at $36,814 and has fallen 95.3% since, to $1,737 in 2025.
Across 191 payments — averaging $560.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$50K
- Pfizer$23K
- Impulse Dynamics (USA) Inc.$12K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$11K
- Novartis$7K
- Abbott$2K
- plus $2K from 14 others
What the payments were for
- Consulting fees$6,3556%
- Speaking & faculty fees$90,37584%
- Travel & lodging$3,4583%
- Food & beverage$6,7946%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 52 | $50,143 |
| Pfizer | 25 | $23,264 |
| Impulse Dynamics (USA) Inc. | 29 | $11,816 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $10,542 |
| Novartis | 7 | $6,945 |
| Abbott | 28 | $2,457 |
| Medtronic(2 entities) | 7 | $663 |
| Edwards Lifesciences | 2 | $271 |
| Boston Scientific | 3 | $198 |
| Abiomed | 2 | $145 |
| Shockwave Medical, Inc | 1 | $128 |
| AstraZeneca | 1 | $120 |
| Biosense Webster, Inc. | 1 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Elutia, Inc. | 1 | $37 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $36 |
| Amgen | 1 | $32 |
| Lexicon Pharmaceuticals, Inc. | 1 | $30 |
| Merck | 2 | $26 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$22,893
- OPTIMIZER$21,286
- LifeVest$9,991
- ENTRESTO$6,872
- JARDIANCE$2,023
- HeartMate 3 Left Ventricular Dev$863
- OPTIMIZER SMART SYSTEM$771
- HeartMate II LVAS$527
- CardioMEMS HF System$271
- Azure$150
- COBALT DR MRI SURESCAN$148
- Evera$135
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$128
- ELIQUIS$125
- WAINUA$120
- GENERAL - THERAPIES$115
- Impella$105
- Arctic Front$104
- MITRIS RESILIA Mitral Valve$103
How this compares
$106,993 in reported general payments places this provider in the 85th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 43 | $57,766 |
| EntrestoSacubitril/Valsartan | 47 | $49,152 |
| EliquisApixaban | 32 | $37,882 |
| FarxigaDapagliflozin Propanediol | 17 | $16,481 |
| Metoprolol Succinate | 101 | $1,386 |
| Atorvastatin Calcium | 67 | $1,204 |
| Bumetanide | 17 | $941 |
| Valsartan | 36 | $873 |
| Nifedipine ErNifedipine | 19 | $616 |
| ClopidogrelClopidogrel Bisulfate | 39 | $610 |
| Carvedilol | 61 | $560 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 13 | $477 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 46 | $468 |
| Lisinopril | 36 | $431 |
| Losartan Potassium | 35 | $428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $50,143 | $57,76643 claims |
| NovartisEntresto | $6,945 | $49,15247 claims |
| PfizerEliquis | $23,264 | $37,88232 claims |
| AstraZenecaFarxiga | $120 | $16,48117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
Other advanced heart failure and transplant cardiology in Philadelphia
- Anjali VaidyaPhiladelphia$762K
- Jesus RamePhiladelphia$336K
- Ileana PinaPhiladelphia$284K
- Jeremy MazurekPhiladelphia$142K
- Lee GoldbergPhiladelphia$130K
- Anjali OwensPhiladelphia$109K
- Joyce WaldPhiladelphia$97K
- Paul MatherPhiladelphia$55K
- Hansie MathelierPhiladelphia$43K
- Nosheen RezaPhiladelphia$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.